A5060035569- Liver Disease Diagnosis and Treatment
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Liver Disease and Transplantation
- Diet, Metabolism, and Disease
- Liver Diseases and Immunity
- Hepatocellular Carcinoma Treatment and Prognosis
- Alcohol Consumption and Health Effects
- Pancreatitis Pathology and Treatment
- Diabetes Treatment and Management
- Cardiovascular Disease and Adiposity
- Diet and metabolism studies
- Lipid metabolism and disorders
- Pancreatic function and diabetes
- Diabetes and associated disorders
- Metabolism, Diabetes, and Cancer
- Systemic Lupus Erythematosus Research
- Endoplasmic Reticulum Stress and Disease
- Pancreatic and Hepatic Oncology Research
- Nutrition and Health in Aging
- Gastroesophageal reflux and treatments
- HIV/AIDS drug development and treatment
- Gastrointestinal Bleeding Diagnosis and Treatment
- Folate and B Vitamins Research
- Chronic Lymphocytic Leukemia Research
Saga University
2016-2025
Noguchi Hospital
2011-2025
Second Affiliated Hospital of Xi'an Jiaotong University
2024
Kaohsiung Medical University
2024
National Sun Yat-sen University
2024
Saga Medical School Hospital
2010-2021
The Japanese Society of Gastroenterological Surgery
2016-2021
Aichi Medical University
2020
Nagoya Medical Center
2020
Hiroshima University
2020
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are increasingly a cause of cirrhosis hepatocellular carcinoma globally. This burden is expected to increase as epidemics obesity, diabetes metabolic syndrome continue grow. The goal this analysis was use Markov model forecast NAFLD using currently available data.A used estimate NASH progression in eight countries based on data for adult prevalence obesity type 2 mellitus (DM). Published estimates expert...
Noninvasive methods have been evaluated for the assessment of liver fibrosis and steatosis in patients with nonalcoholic fatty disease (NAFLD). We compared ability transient elastography (TE) M-probe, magnetic resonance (MRE) to assess fibrosis. Findings from imaging (MRI)-based proton density fat fraction (PDFF) measurements were those TE-based controlled attenuation parameter (CAP) steatosis.We performed a cross-sectional study 142 NAFLD (identified by biopsy; mean body mass index, 28.1...
A reliable and inexpensive noninvasive marker of hepatic fibrosis is required in patients with nonalcoholic fatty liver disease (NAFLD). FIB4 index (based on age, aspartate aminotransferase [AST] alanine [ALT] levels, platelet counts) expected to be useful for evaluating fibrosis. We validated the performance a Japanese cohort NAFLD.The areas under receiver operating characteristic curves (AUROC) six other markers were compared, based data from 576 biopsy-proven NAFLD patients. Advanced was...
Summary Background Pemafibrate is a novel, selective peroxisome proliferator‐activated receptor α modulator (SPPARMα). In mice, improved the histological features of non‐alcoholic steatohepatitis (NASH). patients with dyslipidaemia, it serum alanine aminotransferase (ALT). Aims To evaluate efficacy and safety in high‐risk, fatty liver disease (NAFLD). Methods This double‐blind, placebo‐controlled, randomised multicentre, phase 2 trial 118 (1:1) to either 0.2 mg or placebo, orally, twice...
Abstract Nonalcoholic fatty liver disease (NAFLD) has become a serious public health issue not only in Western countries but also Japan. Within the wide spectrum of NAFLD, nonalcoholic steatohepatitis (NASH) is progressive form that often develops into cirrhosis and increases risk hepatocellular carcinoma (HCC). While definite diagnosis NASH requires biopsy to confirm presence hepatocyte ballooning, hepatic fibrosis most important prognostic factor NAFLD. With so many NAFLD patients, it...
Background & AimsPatients with nonalcoholic fatty liver disease (NAFLD)/metabolic dysfunction-associated steatotic (MASLD) face multifaceted burden which includes impaired health-related quality of life (HRQL) and potential stigmatization. We aimed to assess the in patients NAFLD relationship between experience stigma HRQL.MethodsMembers Global NASH Council created a survey about NAFLD. Participants completed 35-item questionnaire Liver Disease Burden (LDB) (7 domains), 36-item CLDQ-NASH (6...
Acoustic radiation force impulse (ARFI) is a new technology integrated into conventional B-mode ultrasonography. ARFI used to evaluate tissue stiffness in several organs, but this method has not been applied for liver fibrosis.The aim of study was determine whether elastography useful the evaluation fibrosis.This enrolled 55 consecutive patients with chronic disease who underwent biopsy histological assessment fibrosis by Metavir scoring system. Liver and 25 healthy volunteers evaluated...
Non-alcoholic fatty liver disease (NAFLD), a hepatic manifestation of metabolic syndrome, is associated with an increased risk developing lifestyle-related diseases including type 2 diabetes, cardiovascular and cerebral vessel disease. No current drug therapy provides the ideal effects decreasing inflammation while simultaneously improving fibrosis. Liraglutide glucagon-like peptide-1 receptor agonist that affects histological findings in patients non-alcoholic steatohepatitis (NASH). This...
Abstract Increasing evidence indicates that periodontitis affects non-alcoholic fatty liver disease (NAFLD). We examined the relationship between periodontal bacterial infection and clinical/biochemical parameters in 52 NAFLD patients. Anti- Aggregatibacter actinomycetemcomitans ( Aa ) antibody titers correlated positively with visceral fat, fasting plasma insulin, HOMA-IR; negatively liver/spleen ratio. C57BL/6J mice (8-weeks-old) were given or saline (control) for 6 weeks, fed either...
Abstract Background and Aims The pathogenesis of non‐alcoholic fatty liver disease ( NAFLD ) is now focusing on its organ cross‐talk with not only adipose tissue but also systemic skeletal muscle. Cross‐sectional longitudinal studies were conducted to determine the role intramuscular content IMAC measured by computed tomography severity /non‐alcoholic steatohepatitis NASH ). Methods Two hundred eight J apanese patients / diagnosed biopsy enrolled into a cross‐sectional study. Twenty‐one in...
The once-daily, all oral, RBV-free, pangenotypic direct-acting anti-viral regimen consisting of co-formulated NS3/4A protease inhibitor glecaprevir and NS5A pibrentasvir (G/P), demonstrated high rates sustained virologic response (SVR) in phase 2 3 studies outside Japan. CERTAIN-1 is a 3, open-label, multicenter study assessing the safety efficacy G/P (300/120 mg) once daily Japanese patients with chronic HCV GT1 infection. Patients without cirrhosis received 8 weeks or 12...
Sodium glucose cotransporter‐2 inhibitors (SGLT2is) are now widely used to treat diabetes, but their effects on nonalcoholic fatty liver disease (NAFLD) remain be determined. We aimed evaluate the of SGLT2is pathogenesis NAFLD. A multicenter, randomized, controlled trial was conducted in patients with type 2 diabetes The changes glycemic control, obesity, and pathology were compared between participants taking ipragliflozin (50 mg/day for 72 weeks; IPR group) being managed without SGLT2is,...